Literature DB >> 27180916

Establishing Pulmonary and Critical Care Medicine in China: 2016 Report on Implementation and Government Recognition: Joint Statement of the Chinese Association of Chest Physicians and the American College of Chest Physicians.

Renli Qiao1, Darcy Marciniuk2, Nicki Augustyn3, Mark J Rosen4, Huaping Dai5, Rongchang Chen6, Sinan Wu7, Chen Wang8.   

Abstract

This article provides an update on progress toward establishing pulmonary and critical care medicine (PCCM) fellowship training as one of the first four subspecialties to be recognized and supported by the Chinese government. Designed and implemented throughout 2013 and 2014 by a collaborative effort of the Chinese Thoracic Society (CTS) and the American College of Chest Physicians (CHEST), 12 leading Chinese hospitals enrolled a total of 64 fellows into standardized PCCM training programs with common curricula, educational activities, and assessment measures. Supplemental educational materials, online assessment tools, and institutional site visits designed to evaluate and provide feedback on the programs' progress are being provided by CHEST. As a result of this initial progress, the Chinese government, through the Chinese Medical Doctor's Association, endorsed the concept of subspecialty fellowship training in China, with PCCM as one of the four pilot subspecialties to be operationalized nationwide in 2016, followed by implementation across other subspecialties by 2020. This article also reflects on the achievements of the training sites and the challenges they face and outlines plans to enhance and expand PCCM training and practice in China.
Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  critical care; education; internal medicine training; pulmonary

Mesh:

Year:  2016        PMID: 27180916     DOI: 10.1016/j.chest.2016.05.005

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  1 in total

1.  PCCM at the Battlefront Against COVID-19 in Wuhan, China.

Authors:  Sinan Wu; Renli Qiao; Chen Wang
Journal:  Chest       Date:  2020-04-13       Impact factor: 9.410

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.